404 related articles for article (PubMed ID: 17286223)
1. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
2. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
4. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
5. Arsenic-based therapy benefits leukemia patients.
FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
[No Abstract] [Full Text] [Related]
6. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
9. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
10. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
11. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
12. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
13. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
15. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
16. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
[No Abstract] [Full Text] [Related]
17. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
[TBL] [Abstract][Full Text] [Related]
18. Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
Müller E; Seidel MG; Lackner H; Dworzak M; Urban C
Klin Padiatr; 2013 May; 225(3):172-3. PubMed ID: 23625686
[No Abstract] [Full Text] [Related]
19. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
[No Abstract] [Full Text] [Related]
20. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]